Attached files

file filename
EX-10.72 - EXHIBIT 10.72 - Isoray, Inc.v338844_ex10-72.htm

 

 

 

United States Securities And Exchange Commission
Washington, DC 20549

 

FORM 8-K/A

 

Amendment No. 1

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): March 21, 2013

(January 9, 2013)

 

ISORAY, INC.

(Exact name of registrant as specified in its charter)

 

Minnesota 001-33407 41-1458152
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

 

350 Hills Street, Suite 106, Richland, Washington 99354

(Address of principal executive offices) (Zip Code)

 

(509) 375-1202

(Registrant's telephone number)

 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

ITEM 1.01 Entry into a Material Definitive Agreement

 

This Amendment No. 1 (the "Amendment") to the Form 8-K filed on January 15, 2013 (the "Original 8-K") is filed solely to modify the redacted portions of Exhibit 10.72 in response to a comment letter received from the U.S. Securities and Exchange Commission on the Registrant’s confidential treatment request. The remainder of the Original 8-K remains unchanged by this Amendment.

 

ITEM 9.01 Exhibits

 

(c)Exhibits

 

  10.72 Contract, dated January 9, 2013, by and between IsoRay Medical, Inc. and The Open Joint Stock Company ‹‹Isotope›› (confidential treatment requested for redacted portions)

 

 

SIGNATURES

 

In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated:  March 21, 2013    
     
     
  IsoRay, Inc., a Minnesota corporation
   
     
  By:   /s/ Dwight Babcock
    Dwight Babcock, CEO